Abiopharma

🔍 SBLENDORIO GLENN (Executive)

Company: 4D Molecular Therapeutics, Inc. (FDMT)

Report Date: 2026-06-17

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Stock Option (Right to Buy) at $9.42 per share (Derivative)
  Date: 2026-06-17 | Code: A | Expires: 2036-06-16 | equity_swap_involved: false | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
• F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).